Nanomodified strategies to overcome EGFR-tyrosine kinase inhibitors resistance in non-small cell lung cancer

Liao, Zi-Xian; Huang, Kuo‐Yen; Kempson, Ivan M.; Li, Hsin-Jung; Tseng, S-Ja

doi:10.1016/j.jconrel.2020.05.043

Cited by 17 publications

(9 citation statements)

References 108 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, many challenges remain, such as requiring the repeated administration of large doses, neutralization of antibodies, etc. [ 59 ] More and more targeting strategies have been proposed, but the specific interaction mechanism between the targeting unit and the internal environment has not been clarified, which requires the co‐operative efforts of researchers in different fields.…”

Section: Nanotechnology In the Treatment Of Lung Cancermentioning

confidence: 99%

Nanotechnology: Breaking the Current Treatment Limits of Lung Cancer

Liang

et al. 2021

Adv Healthcare Materials

View full text Add to dashboard Cite

Lung cancer is one of the most rapidly growing malignancies in terms of morbidity and mortality. Although traditional treatments have been used for more than 50 years, it is still far from solving the problems of postoperative risks and systemic toxicity. Emerging targeting and immunotherapy are developing continuously and are gaining recognition; eventually, they face the inevitable challenge of drug resistance. Nanotechnology has several important effects on lung cancer treatment, owing to its unique properties. Several nanoparticle‐based treatments have successfully become cancer treatments. Good biocompatibility with higher specific surface area can carry substantial amounts of lung cancer treatment medications while avoiding medication toxicity; editable and modified characteristics give rise to multifunctional nanomedicines; excellent photoelectric effects make lung cancer a multimodal treatment. This article summarizes the breakthroughs achieved by nanotechnology, targeted therapy, and immunotherapy, reflecting the importance and necessity of nanotechnology in the treatment of lung cancer.

show abstract

Section: Nanotechnology In the Treatment Of Lung Cancermentioning

confidence: 99%

Nanotechnology: Breaking the Current Treatment Limits of Lung Cancer

Liang

et al. 2021

Adv Healthcare Materials

View full text Add to dashboard Cite

show abstract

“…There are several kinds of TKIs that are able to inhibit the function of drug efflux pumps in multidrug‐resistant cancer cells, such as breakpoint cluster region‐abelson (BCR‐ABL) TKIs (e.g., imatinib, nilotinib, dasatinib, and ponatinib), epidermal growth factor receptor TKIs (e.g., AST 1306, gefitinib, erlotinib, lapatinib, canertinib, and icotinib), vascular endothelial growth factor TKIs (e.g., telatinib, sunitinib, sorafenib, and motesanib), platelet‐derived growth factor inhibitors (e.g., masitinib and linsitinib), fibroblast growth factor receptor inhibitors (e.g., PD173074), and B‐Raf/MEK/ERK pathway inhibitors (e.g., vemurafenib) (Gu et al, 2020). These TKIs are usually co‐delivered with chemodrugs using nanocarriers to combat multidrug‐resistant tumors (L. Gao, Zhao, et al, 2020c; Hsiao et al, 2019; Liao et al, 2020; H. Wang, Li, et al, 2014a). For instance, Wang et al developed a polymer‐based micelle for the co‐delivery of DOX and lapatinib using an amphiphilic block copolymer.…”

Section: Nanostrategy‐mediated Combination Therapy For Mdr Reversalmentioning

confidence: 99%

Nanomedicines for combating multidrug resistance of cancer

Zhu

Jia

Duan

et al. 2021

WIREs Nanomed Nanobiotechnol

View full text Add to dashboard Cite

Chemotherapy typically involves the use of specific chemodrugs to inhibit the proliferation of cancer cells, but the frequent emergence of a variety of multidrug‐resistant cancer cells poses a tremendous threat to our combat against cancer. The fundamental causes of multidrug resistance (MDR) have been studied for decades, and can be generally classified into two types: one is associated with the activation of diverse drug efflux pumps, which are responsible for translocating intracellular drug molecules out of the cells; the other is linked with some non‐efflux pump‐related mechanisms, such as antiapoptotic defense, enhanced DNA repair ability, and powerful antioxidant systems. To overcome MDR, intense efforts have been made to develop synergistic therapeutic strategies by introducing MDR inhibitors or combining chemotherapy with other therapeutic modalities, such as phototherapy, gene therapy, and gas therapy, in the hope that the drug‐resistant cells can be sensitized toward chemotherapeutics. In particular, nanotechnology‐based drug delivery platforms have shown the potential to integrate multiple therapeutic agents into one system. In this review, the focus was on the recent development of nanostrategies aiming to enhance the efficiency of chemotherapy and overcome the MDR of cancer in a synergistic manner. Different combinatorial strategies are introduced in detail and the advantages as well as underlying mechanisms of why these strategies can counteract MDR are discussed. This review is expected to shed new light on the design of advanced nanomedicines from the angle of materials and to deepen our understanding of MDR for the development of more effective anticancer strategies. This article is categorized under: Nanotechnology Approaches to Biology > Nanoscale Systems in Biology Therapeutic Approaches and Drug Discovery > Nanomedicine for Oncologic Disease

show abstract

“…Cancer is responsible for approximately one in six deaths worldwide, − which seriously affects the health and quality of life of humans. , Targeted therapy is one of the most convenient treatment options, − although it has certain problems, such as poor patient universality and high economic costs. In view of this, patients need to be sorted and treated in the preclinical stage. − …”

Section: Introductionmentioning

confidence: 99%

Discovery of Imaging and Therapeutic Integration Bifunctional Molecules Based on Bio-Orthogonal Reaction and Releasable Disulfide Bond

Wang

Zhang

et al. 2022

Bioconjugate Chem.

View full text Add to dashboard Cite

The application of conventional fluorescent probes in living cells has been limited by excess fluorescence interference, reduced selectivity, and poor permeability. Herein, we describe a convenient solution for overcoming the above limitations based on bio-orthogonal reactions and releasable linkers that provide bifunctional molecules for imaging and therapeutic integration. To reduce the interference of excess fluorescent moieties, a bioorthogonal reaction was applied to activate the fluorescence of the active parent drugs without fluorophores. Moreover, disulfide bonds were incorporated as releasable linkers. After imaging the target protein, the newly yielded fluorophore could be released from the active drugs based on the highly reducing conditions of the tumor. Thus, these bifunctional molecules are comparable in therapeutic activity to the parent drug. These novel imaging and therapeutic integration molecules could be used to realize imagingaided diagnosis and perform efficient real-time monitoring of cancer cells. Our findings are expected to enable efficient and specific imaging and real-time in vivo prognostic monitoring in the clinic.

show abstract

Nanomodified strategies to overcome EGFR-tyrosine kinase inhibitors resistance in non-small cell lung cancer

Cited by 17 publications

References 108 publications

Nanotechnology: Breaking the Current Treatment Limits of Lung Cancer

Nanotechnology: Breaking the Current Treatment Limits of Lung Cancer

Nanomedicines for combating multidrug resistance of cancer

Discovery of Imaging and Therapeutic Integration Bifunctional Molecules Based on Bio-Orthogonal Reaction and Releasable Disulfide Bond

Contact Info

Product

Resources

About